2207 Investors following Panacea Biotec. Share this News with them.
0
Like this story, share it with millions of investors on M3
Vaccine segment grew over 34%: Panacea Biotech
Panacea Biotech declared its last quarter results. The company's Joint MD Rajesh Jain says the growth seen in the vaccines segment, along with that in pharmaceutical formulation saw the company's profits rise.
Panacea Biotech declared its last quarter results. The company's Joint MD Rajesh Jain says the growth seen in the vaccines segment, along with that in pharmaceutical formulation saw the company's profits rise.
Excerpts from CNBC-TV18's exclusive interview with Rajesh Jain:
Q: What's bumped up your profits and sales this quarter?
A: I think it's the growth in the vaccine segment, which is more than 34% and the growth in pharmaceutical formulation, which was about 27.5%. Overall, the whole company has grown on the domestic front.
Even in exports, the pharmaceutical formulation business in export has grown by 73%, whereas vaccines contributed almost Rs 36 crore as compared to the last quarter in the same year, when there were no exports.
Q: What are your operating margins for this quarter?
A: The operating margins for this quarter have also been around 43%.
Q: Given the bump up that you are seeing, particularly in the vaccine segment, what do you think you might finish the year with, in terms of sales and profits?
A: The compounded annual growth for Panacea Biotech, has always been above 25% on an average since the last ten years. And even now, the growth rates are much higher. So we are quite hopeful that this trend will continue.
A: I think it's the growth in the vaccine segment, which is more than 34% and the growth in pharmaceutical formulation, which was about 27.5%. Overall, the whole company has grown on the domestic front. 
